Suppr超能文献

一项针对智力障碍者长期、标签外使用抗精神病药物的开放性停药试验:成功和失败的决定因素。

An Open-Label Discontinuation Trial of Long-Term, Off-Label Antipsychotic Medication in People With Intellectual Disability: Determinants of Success and Failure.

机构信息

Centre for Intellectual Disabilities and Mental Health/GGZ Drenthe Mental Health Institute, the Netherlands.

University of Groningen, University Medical Centre Groningen, University of Groningen, Department of Psychiatry, the Netherlands.

出版信息

J Clin Pharmacol. 2018 Nov;58(11):1418-1426. doi: 10.1002/jcph.1271. Epub 2018 Jun 19.

Abstract

Although physicians are aware of the risks of prescribing long-term off-label antipsychotics in people with intellectual disability, attempts to discontinue often fail. This study aimed to identify potential determinants of successful and failed discontinuation. Long-term off-label antipsychotics were tapered in 14 weeks, with 12.5% of baseline dose every 2 weeks. Participants living in facilities offered by intellectual disability service providers, ≥6 years, with an IQ <70 were eligible to discontinue antipsychotic use, as judged by their physicians. The primary outcome was achievement of complete discontinuation at 16 weeks; changes in the Aberrant Behavior Checklist (ABC) and its 5 subscales were secondary outcomes. Potential determinants of the success or failure in discontinuing antipsychotics were psychotropic drug use and participants' living circumstances, medical health conditions, and severity of behavioral symptoms and neurologic side effects. Of 499 eligible clients, 129 were recruited. Reasons for client non-participation were clinician concerns that discontinuation might increase challenging behaviors and changes in clients' environment. Of the 129 participants, 61% had completely discontinued antipsychotics at 16 weeks, 46% at 28 weeks, and 40% at 40 weeks. ABC total scores increased in 49% of participants with unsuccessful discontinuation at 16 weeks. Autism, higher dose of antipsychotic drug, higher ABC and akathisia scores, and more-frequent worsening of health during discontinuation were associated with a lower incidence of complete discontinuation. Thus, in a selected sample of participants whom responsible clinicians had deemed discontinuation of antipsychotics could be attempted, 40% had achieved and maintained discontinuation at end of follow-up. Physicians should try to address patients' conditions that may hamper discontinuation.

摘要

尽管医生意识到为智力障碍患者开具长期超适应证抗精神病药物存在风险,但停药尝试往往会失败。本研究旨在确定成功和失败停药的潜在决定因素。在 14 周内逐渐减少长期超适应证抗精神病药物的剂量,每 2 周减少基线剂量的 12.5%。有资格停药的参与者是居住在智力障碍服务提供商提供的设施中的患者,年龄≥6 岁,智商<70,由医生判断。主要结局是在 16 周时达到完全停药;异常行为检查表(ABC)及其 5 个分量表的变化是次要结局。抗精神病药物停药成功或失败的潜在决定因素是精神药物的使用以及参与者的生活环境、医疗健康状况以及行为症状和神经副作用的严重程度。在 499 名符合条件的患者中,有 129 名被招募。患者未参与的原因是临床医生担心停药可能会增加挑战性行为和患者环境的变化。在 129 名参与者中,有 61%在 16 周时完全停止了抗精神病药物,46%在 28 周时,40%在 40 周时。在 16 周时未成功停药的 49%的参与者中,ABC 总分增加。自闭症、抗精神病药物剂量较高、ABC 和静坐不能评分较高以及停药期间健康状况恶化更频繁与完全停药的发生率较低相关。因此,在一组经有责任心的医生判断可以尝试停药的选定参与者中,有 40%在随访结束时实现并维持了停药。医生应该尽力解决可能妨碍停药的患者病情。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验